
CLBT Stock Forecast & Price Target
CLBT Analyst Ratings
Bulls say
Cellebrite DI is attractive fundamentally because it is still generating 30%-plus free cash flow margins while delivering strong top-line and operating growth, including 20% year-over-year ARR growth to $528.5 million, 18% revenue growth to $149.0 million, and Adjusted EBITDA of $53.6 million at a 36.0% margin. Its raised EBITDA guidance to $163 million to $166 million, along with non-GAAP gross margin of 85.7%, signals durable profitability and operating leverage despite near-term execution issues. The bullish case is further supported by new-product momentum in Genesis and D&I, where healthy adoption, strong demand, and improving product packaging could extend growth and strengthen investor confidence over time.
Bears say
Cellebrite DI is facing a negative outlook because its recent growth appears increasingly dependent on lower-quality revenue from non-recurring and professional services, while subscription revenue missed expectations and management pointed ARR guidance toward the low end of $550 million to $560 million. The company also flagged weaker 4QCY26 revenue of $145 million to $150 million, longer sales cycles, and slower conversion uplift from Inseyets and Corellium, suggesting demand visibility is deteriorating rather than improving. With roughly 90% of revenue tied to law enforcement and government customers through 2024, Cellebrite remains exposed to budget volatility, procurement friction, and reputational or regulatory risks that could pressure future ARR growth and retention.
This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.
CLBT Analyst Forecast & Price Prediction
Start investing in CLBT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cellebrite DI Ltd (CLBT) Forecast
CLBT Analyst Forecast & Price Prediction
Start investing in CLBT
Order type
Buy in
Order amount
Est. shares
0 shares